Showing 1531-1540 of 1630 results for "".
- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Merz On The Move: Reflections On Fiscal Year 2015/16https://modernaesthetics.com/news/merz-on-the-move-reflections-on-fiscal-year-201516/2472311/Merz Pharma’s core business has grown by 8.9 percent from EUR 809.8 million to EUR 881.9 million in fiscal 2015/16, the company reports. The company’s total revenue of EUR 1,092.9 million has declined by 5.5 percent compared to previous year
- Recently Retired American Academy of Facial Plastic and Reconstructive Surgery CEO Receives AMA Lifetime Achievement Awardhttps://modernaesthetics.com/news/recently-retired-american-academy-of-facial-plastic-and-reconstructive-surgery-ceo-receives-ama-lifetime-achievement-award/2472317/The American Medical Association (AMA) has presented the Medical Executive Lifetime Achievement Award to Stephen C. Duffy, former executive vice president and CEO of the American Academy of Facial Plastic and Reconstructive Sur
- E. Ross, MD, FAADhttps://modernaesthetics.com/profiles/e-ross-md-faad/7rBw05/
- Todd E. Schlesinger, MDhttps://modernaesthetics.com/profiles/todd-e-schlesinger-md/jPKAQ2/
- Eric Raiblehttps://modernaesthetics.com/profiles/eric-raible/jMkWQn/
- Elizabeth Houshmand, MDhttps://modernaesthetics.com/profiles/elizabeth-houshmand-md/jlDY5Q/
- Jeffrey Epstein, MD, FACS, FISHRShttps://modernaesthetics.com/profiles/jeffrey-epstein-md-facs-fishrs/j5eaMx/
- Dendy Engelman, MDhttps://modernaesthetics.com/profiles/dendy-engelman-md/OYJX3n/
- Contributing Editorhttps://modernaesthetics.com/profiles/contributing-editor/7rB8NP/